Engineered Monocytic Cells for Osteopetrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteopetrosis, such as bone marrow transplantation, have limited success with a 48% overall survival rate at 6 years and are plagued by complications, highlighting the need for alternative therapeutic approaches that can effectively treat or prevent the condition.
Innovation Solution
Administration of engineered monocytic cells expressing specific genes like CA2, CLCN7, CTSK, CSF1R, IKBKG, ITGB3, OSTM1, PLEKHM1, TCIRG1, TNFRSF11A, and TNFSF11, either from healthy donors or genetically modified to correct deficiencies, via intravenous injection, infusion, or transfusion to treat or prevent osteopetrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone marrow transplantation is used to treat osteopetrosis, then osteoclast function can be restored, but overall survival rate remains low at 48% at 6 years with significant complications
Solution Approach 1:
The patent extracts the essential therapeutic component (osteoclasts) from the complex bone marrow transplantation procedure. By directly administering isolated or engineered osteoclasts rather than performing full bone marrow transplantation, the treatment achieves the desired therapeutic effect while eliminating many of the complications associated with comprehensive marrow transplantation, thereby improving survival rates and reducing harmful side effects
Solution Approach 2:
The patent uses engineered osteoclasts as an intermediary therapeutic agent that can be genetically modified to express specific genes (such as cathepsin K, tartrate-resistant acid phosphatase, or other osteoclast-specific enzymes) before administration. This intermediary approach allows for precise control of osteoclast function and reduces the risk of complications compared to direct bone marrow transplantation
2Adaptability or versatility
If bone marrow transplantation is performed, then osteoclast development can occur, but the procedure has approximately 48% overall survival at 6 years
Solution Approach 1:
The patent applies preliminary action by pre-differentiating and pre-engineering osteoclasts in vitro before administration to the patient. Osteoclast precursors are cultured and differentiated into mature osteoclasts, and genetically engineered to express therapeutic genes before being transplanted. This preliminary preparation ensures that the administered cells are fully functional and therapeutically active, improving treatment reliability and survival rates
Solution Approach 2:
The patent employs a disposable approach by using genetically engineered osteoclasts that are cultured in vitro and administered as a finite therapeutic dose. These engineered osteoclasts serve as a temporary but effective therapeutic intervention that can be renewed if necessary, avoiding the long-term commitment and risks associated with bone marrow transplantation while maintaining treatment effectiveness
Data Source
Figure 1A~1C
Figure 1D~1H
Figure 1I
AI summary
Disclosed herein are methods and compositions for treating, preventing, or ameliorating osteopetrosis. In some embodiments, the present technology relates to administering a composition comprising a therapeutically effective amount of engineered monocytic cells or wild-type monocytic cells from a healthy donor to a subject suffering from or at risk for osteopetrosis.